<?xml version="1.0" encoding="UTF-8"?>
<p>Asthma and chronic obstructive pulmonary disease (COPD) are very common inflammatory diseases of the airways. The World Health Organization (WHO) estimates that asthma accounts for 1 in every 250 deaths worldwide (
 <xref ref-type="bibr" rid="B84">O’Sullivan, 2005</xref>). The prevalence of asthma in developed countries is approximately 10% in adults and even higher in children, while in developing countries, the prevalence is lower but increasing rapidly (
 <xref ref-type="bibr" rid="B6">Barnes, 2008</xref>). In the case of COPD, WHO consensus reports forecast that this disorder will be ranked the third cause of mortality in the world by 2020 (Global initiative for chronic obstructive lung disease [GOLD], 2013
 <sup>
  <xref ref-type="fn" rid="fn01">1</xref>
 </sup>). Acute deterioration of symptoms and lung function, which often results in respiratory failure, is a so-called “exacerbation,” and it is an important and severe social and medical burden in both diseases.
</p>
